Europital, a global provider of medical management services for clinical research and drug development, is opening a UK site to further expand its services to the UK biotech industry.
The new R&D facility will add to Biocon’s 200,000-square-foot R&D site in Bengaluru. In all, Biocon has 28 molecules in development, including 11 under a partnership with Mylan, a few others with Novartis' Sandoz and the remainder independently.
The site now has a new Product Development & QC Lab area with 13 processing suites, two new packaging suites, serialization, and new manufacturing suites.